AiVita Biomedical Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
21
- Latest Deal Type
-
Series B2
- Latest Deal Amount
-
$19M
- Investors
-
9
AiVita Biomedical General Information
Description
Operator of a biotechnology company intended for the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. The company engages in the development of personalized vaccines for the prevention of infectious diseases and the treatment of cancer and its novel vaccine kit ensures pathogen readiness against emerging and evolving threats, enabling the medical system to bring cell-based therapies and treatments to the patients who need them.
Contact Information
Website
www.aivitabiomedical.comCorporate Office
- 18301 Von Karman Avenue
- Suite 130
- Irvine, CA 92612
- United States
Corporate Office
- 18301 Von Karman Avenue
- Suite 130
- Irvine, CA 92612
- United States
AiVita Biomedical Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series B2) | 30-Aug-2022 | $19M | Completed | Generating Revenue | ||
| 5. Early Stage VC (Series B2) | 18-Dec-2019 | Completed | Generating Revenue | |||
| 4. Grant | 17-Jul-2018 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B) | 11-Jun-2018 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 13-Mar-2018 | $5.5M | $5.5M | Completed | Clinical Trials - Phase 2 | |
| 1. Grant | 29-Sep-2016 | $22M | Completed | Clinical Trials - Phase 2 |
AiVita Biomedical Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | ||||||||
| Series B | ||||||||
| Series A | 994,218 | $0.001000 | 8% | $6.27 | $6.27 | 1x | $6.27 | 10.1% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
AiVita Biomedical Comparisons
Industry
Financing
Details
AiVita Biomedical Competitors (96)
One of AiVita Biomedical’s 96 competitors is 3T Biosciences, a Venture Capital-Backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| 3T Biosciences | Venture Capital-Backed | South San Francisco, CA | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Viriom | Venture Capital-Backed | Rockville, MD | ||||
| Boehringer Ingelheim | Corporation | Ingelheim Am Rhein, Germany | ||||
| Centrose | Venture Capital-Backed | Middleton, WI |
AiVita Biomedical Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
AiVita Biomedical Patents
AiVita Biomedical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021284302-A1 | Autologous dendritic cell vaccine kit and uses | Pending | 02-Jun-2020 | ||
| CA-3184883-A1 | Autologous dendritic cell vaccine kit and uses | Pending | 02-Jun-2020 | ||
| EP-4157340-A1 | Autologous dendritic cell vaccine kit and uses | Pending | 02-Jun-2020 | ||
| US-20230210982-A1 | Autologous dendritic cell vaccine kit and uses | Pending | 02-Jun-2020 | ||
| EP-4157340-A4 | Autologous dendritic cell vaccine kit and uses | Pending | 02-Jun-2020 | A61K39/215 |
AiVita Biomedical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
AiVita Biomedical Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Big Sky Partners | Venture Capital | Minority | ||
| Ci:z Investment | Corporate Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| SDV Holdings | Venture Capital | Minority | ||
| SFC (South Korea) | Corporation | Minority |
AiVita Biomedical FAQs
-
When was AiVita Biomedical founded?
AiVita Biomedical was founded in 2016.
-
Where is AiVita Biomedical headquartered?
AiVita Biomedical is headquartered in Irvine, CA.
-
What is the size of AiVita Biomedical?
AiVita Biomedical has 21 total employees.
-
What industry is AiVita Biomedical in?
AiVita Biomedical’s primary industry is Pharmaceuticals.
-
Is AiVita Biomedical a private or public company?
AiVita Biomedical is a Private company.
-
What is the current valuation of AiVita Biomedical?
The current valuation of AiVita Biomedical is .
-
What is AiVita Biomedical’s current revenue?
The current revenue for AiVita Biomedical is .
-
How much funding has AiVita Biomedical raised over time?
AiVita Biomedical has raised $64.5M.
-
Who are AiVita Biomedical’s investors?
Big Sky Partners, Ci:z Investment, , SDV Holdings, and SFC (South Korea) are 5 of 9 investors who have invested in AiVita Biomedical.
-
Who are AiVita Biomedical’s competitors?
3T Biosciences, Genentech, Viriom, Boehringer Ingelheim, and Centrose are some of the 96 competitors of AiVita Biomedical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
